3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Trastuzumab
242
Paclitaxel
223
Fulvestrant
196
Capecitabine
182
Docetaxel
164
Letrozole
142
pembrolizumab
115
Carboplatin
100
exemestane
98
Gemcitabine
98
Cyclophosphamide
92
palbociclib
86
Anastrozole
83
pertuzumab
78
Lapatinib
73
Bevacizumab
71
ribociclib
68
130-nm albumin-bound paclitaxel
66
abemaciclib
59
eribulin
58
Doxorubicin
55
Vinorelbine
51
Injections
47
Ado-Trastuzumab Emtansine
47
Tamoxifen
45
Everolimus
44
Albumin-Bound Paclitaxel
44
atezolizumab
35
trastuzumab deruxtecan
34
Nivolumab
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Blood Component Removal
×
Breast
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled